CARBIOS
24.6.2021 07:02:13 CEST | Business Wire | Press release
The promise of endlessly recycled PET plastic is one step closer today, as the Consortium – Carbios, L’Oréal, Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe – announces the successful production of the world’s first food-grade PET plastic bottles produced entirely from enzymatically recycled plastic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005867/en/
Each Consortium company has successfully manufactured sample bottles – based on Carbios’ enzymatic PET recycling technology – for some of their leading products including: Biotherm®, Perrier®, Pepsi Max®** and Orangina®.
Today’s announcement is the culmination of nearly 10 years’ research and development by Carbios to create a new process and supercharge an enzyme naturally occurring in compost heaps that normally breaks down leaf membranes of dead plants. By adapting this enzyme, Carbios has fine-tuned the technology and optimized this enzyme to break down any kind of PET plastic (regardless of color or complexity) into its building blocks, which can then be turned back into like-new, virgin-quality plastic.
Carbios’ patented enzymatic PET recycling process enables a wide variety of PET plastics to be recycled into virgin quality, food grade rPET. PET plastics that would otherwise go to waste or be incinerated, can now be brought back into a continuous circular system of recycling. And this can be achieved at high speed – breaking down 97% of plastic in just 16 hours – 10,000 times more efficient than any biological plastic recycling trial to date (peer-reviewed article in Nature ).
Together, these brands will work to scale this innovation to help meet the global demand for sustainable packaging solutions. In September 2021, Carbios will break ground on a demonstration plant, before launching a 40,000 tons capacity industrial facility, by 2025.
Commenting on the announcement, Carbios’ CEO Jean Claude Lumaret commented: “In a world first, we have created food-grade clear bottles from enzymatically recycled colored and complex plastic with identical properties to virgin PET, and in partnership with the Consortium, we have proved the viability of the technology with the world’s leading brands. This is a truly transformational innovation that could finally fully close the loop on PET plastic supply globally, so that it never becomes waste.”
Jacques Playe, L’Oréal’s Global Head of Packaging and Product Development added: “We have been working with Carbios since 2017 to develop this first bottle made from PET derived from enzymatic recycling technology, an alternative to mechanical recycling. We are pleased to announce today the feasibility of these bottles in a pilot phase and are delighted to be in a position to create the packaging of the future with our partners. This is a promising innovation for the years to come that demonstrates our commitment to bring to market more environmentally friendly packaging and which is part of a circularity initiative begun more than 15 years ago”.
Jean-Francois Briois, Head of Packaging Material Science and Environmental Sustainability Nestlé Waters global R&D added: “It is very exciting to see that the quality of the prototype bottles made from colored recycled PET materials is virtually identical to clear virgin PET. When we reach industrial scale, this enzymatic recycling technology will enable us to produce high-quality rPET bottles and help Nestlé Waters in our journey to boost the circular economy and reduce the use of virgin plastics.”
Ron Khan, Global VP of Packaging, Beverages, PepsiCo added: “PepsiCo is committed to building a circular economy to achieve our vision that packaging never becomes waste. We are dedicated to reducing the virgin plastic we use and with the breakthrough Carbios enzymatic recycling technology, we can help keep valuable material in the circular economy, reduce waste and take another step toward a truly closed loop system.”
Roberto Vanin, Chief R&D Officer, Suntory Beverage & Food Europe, added: “The global issue of plastic waste requires transformational thinking, creative partnerships and innovative brands coming together to seek out new solutions. Continued investment in new ways of tackling waste and creating true circularity such as this ground-breaking technology from Carbios will be key to Suntory Beverage & Food Europe achieving its 100% sustainable plastic ambition.”
Enzymatic recycling overcomes the issue of degradation in conventional recycling and can be used on any type of PET plastic. Because Carbios’ recycling process works under mild conditions, it could also lower the carbon footprint of PET waste treatment by saving 30% of CO2 emissions compared to a conventional end of life mix of incineration and landfill, taking virgin PET production substitution into account.***
The successful completion of these initial food-grade bottles is a major milestone in the Consortium’s validation of Carbios’ technology. This partnership is part of a growing trend amongst brands to collaborate across industries to tackle these global challenges, working towards a world of circularity, where we limit the production of virgin plastic.
Carbios will license its technology to PET manufacturers worldwide, accelerating the global adoption of enzymatic recycling for all kinds of PET based products.
Notes to Editors
To book interviews or to request further information or images, please contact lon-carbios@ketchum.com
** Pepsi Max® also known as Pepsi Black or Pepsi Zero Sugar in other global markets.
*** Preliminary Life Cycle Assessment of Carbios PET recycling process, 2021
About Enzymatic Recycling
Around 70 million tons of PET plastic is manufactured globally every year – equal to around 20% of all plastic – but through repeated conventional thermomechanical processes, the plastic used in packaging is degraded over time and requires new virgin plastic to retain its quality.
Carbios has successfully hyper-charged a naturally occurring enzyme from compost heaps that breaks down leaf membranes of dead plants. PET plastic is made from a string of building blocks also called monomers and this optimized enzyme is super-efficient at cutting the PET plastic into these building blocks: terephthalic acid and ethylene glycol. Those monomers can then be recombined to recreate the PET polymer, at food grade quality, in an infinite, virgin-quality loop.
About Carbios
Carbios, a green biotech company, develops biological and innovative processes to revolutionize the end of life of plastics and textiles. Through its unique approach of combining enzymes and plastics, Carbios aims to address new consumer expectations and the challenges of a broader energy transition by taking up a major challenge of our time: plastic and textile pollution. Carbios was named one of the World Economic Forum’s Technology Pioneers of 2021 .
Carbios and L’Oréal founded the Consortium in 2017 and were joined in 2019 by Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe.
For more information, please visit http://www.carbios.com/en/
For more information, please visit:
https://www.suntorybeverageandfood-europe.com
https://www.linkedin.com/company/suntory-beverage-&-food-europe-limited/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005867/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
